Expression of the costimulatory molecule BB-1 and its receptors in patients with scleroderma-polymyositis overlap syndrome

Journal of the Neurological Sciences

Volumn 205, Issue 1, 2002, Pages 65-70

  Murata, Ken Ya ^a   Sugie, Kazuma ^a   Takamure, Miwa ^a   Ueno, Satoshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Antigen presenting cell; BB 1; Costimulatory molecule; Overlap syndrome; Polymyositis; Scleroderma

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; COSTIMULATORY MOLECULE BB 1; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; CELL CONTACT; CELL INVASION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; MUSCLE BIOPSY; MUSCLE CELL; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCLERODERMA; T LYMPHOCYTE;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD4; ANTIGENS, CD8; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BACTERIAL PROTEINS; BIOPSY; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOCONJUGATES; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; POLYMYOSITIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCLERODERMA, SYSTEMIC;

EID: 0037116094     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(02)00309-X     Document Type: Article

References (26)

1. Averbuch-Heller L., Steiner I., Abramsky O. Neurologic manifestations of progressive systemic sclerosis. Arch. Neurol. 49:1992;1292-1295.
2. Clements P.J., Furst D.E., Campion D.S., Bohan A., Harris R., Levy J.et al. Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. Arthritis Rheum. 21:1978;62-71.
3. Hietaharju A., Jääskeläinen S., Kalimo H., Hietarinta M. Peripheral neuromuscular manifestations in systemic sclerosis (scleroderma). Muscle Nerve. 16:1993;1204-1212.
4. Ringel R.A., Brick J.E., Brick J.F., Gutmann L., Riggs J.E. Muscle involvement in the scleroderma syndromes. Arch. Intern. Med. 150:1990;2550-2552.
5. Olsen N.J., King L.E., Park J.H. Muscle abnormalities in scleroderma. Rheum. Dis. Clin. North Am. 22:1996;783-796.
6. Goebels N., Michaelis D., Wekerle H., Hohlfeld R. Human myoblasts as antigen-presenting cells. J. Immunol. 15:1992;661-667.
7. Behrens L., Kerschensteiner M., Misgeld T., Goebels N., Wekerle H., Hohlfeld R. Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J. Immunol. 161:1998;5943-5951.
8. Boussiotis V.A., Freeman G.J., Gribben J.G., Daley J., Gray G., Nadler L.M. Activated human B lymphocytes express three CTLA-4 counter receptors that costimulate T-cell activation. Proc. Natl. Acad. Sci. U. S. A. 90:1993;11059-11063.
9. Freeman G.J., Cardoso A.A., Boussiotis V.A., Anumanthan A., Groves R.W., Kupper T.S.et al. The BB-1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counter receptor. J. Immunol. 161:1998;2708-2715.
10. Abbas A.K., Lichtman A.H., Pober J.S. Cellular and molecular immunology. 3rd ed. 1997;278-296 Saunders, Philadelphia.
11. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 23:1980;581-590.
12. Bohan A., Peter J.B. Polymyositis and dermatomyositis. N. Engl. J. Med. 292:1975;344-347.
13. Bohan A., Peter J.B. Polymyositis and dermatomyositis. N. Engl. J. Med. 292:1975;403-407.
14. Illa I., Dinsmore S., Dalakas M.C. Immune-mediated mechanisms and immune activation of fibroblasts in the pathogenesis of eosinophilia-myalgia syndrome induced by L-tryptophan. Human Pathol. 24:1993;702-709.
15. Murata K., Dalakas M.C. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am. J. Pathol. 155:1999;453-460.
16. Murata K., Dalakas M.C. Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNAs in chronic inflammatory demyelinating polyneuropathy. Brain. 123:2000;1660-1666.
17. Dariavach P., Mattéi M.G., Golstein P., Lefranc M.P. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur. J. Immunol. 18:1988;1901-1905.
18. Ercolani L., Florence B., Denaro M., Alexander M. Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. J. Biol. Chem. 263:1988;15335-15341.
19. Lee K.P., Taylor C., Petryniak B., Turka L.A., June C.H., Thompson C.B. The genomic organization of the CD28 gene implications for the regulation of CD28 mRNA expression and heterogeneity. J. Immunol. 145:1990;344-352.
20. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies: I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscles fibers invaded by T cells. Ann. Neurol. 16:1984;193-208.
21. Reiser H., Stadecker M.J. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N. Engl. J. Med. 335:1996;1369-1377.
22. Nickoloff B.J., Mitra R.S., Lee K., Turka L.A., Green J., Thompson C.et al. Discordant expression of CD28 ligands, BB-1, and B7 on keratinocytes in vitro and psoriatic cells in vivo. Am. J. Pathol. 142:1993;1029-1040.
23. Simon J.C., Dietrich A., Mielke V., Wuttig C., Vanscheidt W., Linsley P.S.et al. Expression of the B7/BB1 activation antigen and its ligand CD28 in T-cell-mediated skin diseases. J. Invest. Dermatol. 103:1994;539-543.
24. Dalakas M.C. Molecular immunology and genetics of inflammatory muscle diseases. Arch. Neurol. 55:1998;1509-1512.
25. Lundberg I., Brengman J.M., Engel A.G. Analysis of cytokine expression in muscles in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J. Neuroimmunol. 63:1995;9-16.
26. Abbas A.K., Lichtman A.H., Pober J.S. Effector mechanisms of T cell-mediated immune reactions. Cellular and molecular immunology. 1997;278-296 Saunders, Philadelphia.